Chimeric yellow fever-dengue tetravalent vaccine (ChimeriVax™-DEN1-4):: Precilnical safety and efficacy in non-human primates

被引：0
|
作者：
Draper, K
Fournier, C
Levenbook, I
Myers, G
Guirakhoo, F
Monath, TP
机构：
[1] Charles River Labs, SierraDiv, Sparks, NV USA
[2] Aventis Pasteur, Marcy Letoile, France
[3] Acambis Inc, Cambridge, MA USA
来源：
ANTIVIRAL RESEARCH | 2004年 / 62卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
148
引用
收藏
页码：A85 / A85
页数：1
相关论文
共 37 条
  • [31] Safety and efficacy of adenovirus-mediated transfer of the human aquaporin-1 cDNA to irradiated parotid glands of non-human primates
    Anne C O'Connell
    Lorena Baccaglini
    Philip C Fox
    Brian C O'Connell
    Daniel Kenshalo
    Hilda Oweisy
    A T M Shamsul Hoque
    Di Sun
    Laurie L Herscher
    Virginia R Braddon
    Christine Delporte
    Bruce J Baum
    [J]. Cancer Gene Therapy, 1999, 6 : 505 - 513
  • [32] Safety and efficacy of adenovirus-mediated transfer of the human aquaporin-1 cDNA to irradiated parotid glands of non-human primates
    O'Connell, AC
    Baccaglini, L
    Fox, PC
    O'Connell, BC
    Kenshalo, D
    Oweisy, H
    Hoque, ATMS
    Sun, D
    Herscher, LL
    Braddon, VR
    Delporte, C
    Baum, BJ
    [J]. CANCER GENE THERAPY, 1999, 6 (06) : 505 - 513
  • [33] Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agon-istic trimerbody in non-human primates
    Navarro, Rocio
    Frago, Susana
    Hangiu, Oana
    Erce-Llamazares, Ainhoa
    Lazaro-Gorines, Rodrigo
    Morcillo, Miguel A.
    Rodriguez-Peralto, Jose L.
    Sanz, Laura
    Compte, Marta
    Alvarez-Vallina, Luis
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2024, 487
  • [34] Immune Modulation through 4-1BB Enhances SIV Vaccine Protection in Non-Human Primates against SIVmac251 Challenge
    Hirao, Lauren A.
    Hokey, David A.
    Morrow, Matthew P.
    Jure-Kunkel, Maria N.
    Weiner, David B.
    [J]. PLOS ONE, 2011, 6 (09):
  • [35] Evaluation of replication, immunogenicity and protective efficacy of a live attenuated cold-adapted pandemic H1N1 influenza virus vaccine in non-human primates
    Boonnak, Kobporn
    Paskel, Myeisha
    Matsuoka, Yumiko
    Vogel, Leatrice
    Subbarao, Kanta
    [J]. VACCINE, 2012, 30 (38) : 5603 - 5610
  • [36] Efficacy and safety of ocular AAV mediated optogenetic therapy for retinitis pigmentosa in rd1 mice and non-human primates support the first-in-human clinical trial of GS030
    Douar, A.
    Bouquet, C.
    Pruneau, D.
    Thomasson, N.
    Chavas, J.
    Galluppi, F.
    Dalkara, D.
    Besnosman, R.
    Chenegros, G.
    Picaud, S.
    Sahel, J.
    [J]. HUMAN GENE THERAPY, 2017, 28 (12) : A4 - A4
  • [37] A Multi-Mechanistic Anti-Angiogenic AAV Gene Therapy Product Candidate, 4D-150, for the Treatment of Wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME): Intravitreal Biodistribution, Transgene Expression, Safety and Efficacy in Non-Human Primates
    Francis, Peter J.
    Francis, Peter J.
    Burns, Christian
    Szymanski, Paul
    Leong, Meredith
    Mohaghegh, Nima
    Schmitt, Christopher
    Klein, Austin
    Croze, Roxanne H.
    Calton, Melissa A.
    Khoday, Devi
    Kotterman, Melissa
    Barglow, Katherine
    Schaffer, David
    Kirn, David
    [J]. MOLECULAR THERAPY, 2021, 29 (04) : 31 - 32
1234